Budesonide Inhalation Suspension
Product Images NDC 60687-524

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Budesonide Inhalation (NDC 60687-524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton

Budesonide Inhalation Suspension 0.5 mg/2 mL label from American Health Packaging. The label includes usage instructions, storage directions to keep upright, Rx only indication, and specifies 30 unit-dose 2 mL ampules each in a foil pouch. The label design features the product name, strength, and manufacturer logo prominently.*

FDA Label Image

Figure 1

A line graph titled 'Nighttime Asthma Change from Baseline' depicting mean change in nighttime asthma symptoms over 12 weeks. The Y-axis shows mean change from baseline, ranging approximately from 0 to -0.6. The X-axis shows time intervals: Baseline, Week 0-2, Week >2-4, Week >4-6, Week >6-8, Week >8-10, Week >10-12, Weeks 0-12. Four lines represent treatment groups: Placebo, 0.25 mg once daily, 0.5 mg once daily, and 1.0 mg once daily. The graph shows symptom reduction over time for all doses compared to placebo. P-values are listed for 0.25 mg, 0.5 mg, and 1.0 mg groups.*

FDA Label Image

Figure 2

A line graph titled 'Nighttime Asthma Change from Baseline' showing mean change from baseline nighttime asthma symptoms over a 12-week period. Three lines represent Placebo, 0.25 mg twice daily, and 0.5 mg twice daily treatments, with time intervals plotted on the x-axis and mean change on the y-axis. P-values for 0.25 mg and 0.5 mg doses are noted as 0.022 and 0.021, respectively.*

FDA Label Image

Figure 3

A line graph titled 'Nighttime Asthma Change from Baseline' showing mean change in nighttime asthma symptoms over 12 weeks for placebo and various budesonide inhalation dosages. The x-axis is time in weeks grouped in intervals up to 12 weeks, and the y-axis is mean change from baseline symptoms. Lines represent placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily. Statistical p-values for each dosage group compared to placebo are shown below the graph.*

FDA Label Image

Foil

Label for Budesonide Inhalation Suspension 0.5 mg/2 mL by American Health Packaging. The label states it is for inhalation only and describes dosage form as a unit-dose ampule of suspension. Storage and usage instructions, inactive ingredients, and regulatory information are included. The label includes the product NDC 60687-524 and indicates it is Rx only.*

FDA Label Image

Ifu Figure 2

An instructional illustration showing a hand gripping a small vial or ampule, with a circular arrow indicating a twisting action to open or prepare the container, related to Budesonide Inhalation suspension usage.*

FDA Label Image

Ifu Figure 3

Instructional illustration showing a person holding an ampule with one hand and using the other hand to twist and open the top of the ampule, indicated by a curved arrow. This image is related to the preparation or administration of Budesonide Inhalation Suspension.*

FDA Label Image

Ifu Figure 4

An instructional line drawing showing a person holding a small container with one hand and shaking or manipulating a device with the other hand. This likely demonstrates preparation or use of Budesonide Inhalation suspension for respiratory inhalation.*

FDA Label Image

Structure

Chemical structure diagram of Budesonide, the active ingredient in Budesonide Inhalation suspension .5 mg/2mL. The image shows the detailed molecular structure with labeled atoms and bonds representing the steroid framework characteristic of budesonide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.